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A Wake-up Call for Type 2 Diabetes?
Shanta J. Persaud, Ph.D., and Peter M. Jones, Ph.D.
The incidence of diabetes is increasing at an 
alarming rate, with a predicted worldwide inci-
dence of more than 640 million people by 2040. 
The vast majority of persons with diabetes have 
type 2 diabetes, which occurs when insulin resis-
tance is present in fat and muscle cells, hepatic 
glucose output is enhanced, and insulin secretion 
fails to compensate. A direct link between obesity 
and the development of type 2 diabetes is well 
established, but there is also a strong heritability 
component. Genetic studies have identified more 
than 150 so-called risk alleles for type 2 diabetes 
— variations in genes that increase a person’s 
susceptibility to diabetes.
The majority of these gene variants affect 
genes encoding intracellular proteins that medi-
ate the secretion of insulin by beta cells or that 
transduce the effects of insulin in target tissues. 
However, not all candidate genes encode pro-
teins that function within the cell: one that does 
not is MTNR1B, which encodes MT2, a cell-surface 
G-protein–coupled receptor (GPCR). This recep-
tor is expressed on islet beta cells and is activated 
by changes in circulating levels of the pineal-
derived hormone melatonin. Persons who have a 
variant of MTNR1B are at increased risk for the 
development of type 2 diabetes,1 and a recent 
study by Tuomi and colleagues,2 who discovered 
the genetic association, investigated the effects 
of melatonin, by means of the MT2 receptor, on 
beta-cell function.
This group screened islets that were isolated 
from pancreases of organ donors and found that 
persons who had the MTNR1B risk variant also 
had higher levels of MTNR1B messenger RNA in 
their islets than those without the variant. They 
also found that the administration of melatonin 
to rat beta cells that overexpress this receptor in-
hibited the glucose-induced secretion of insulin. 
They went on to discover that melatonin reduced 
the levels of cyclic AMP in rat beta cells, a find-
ing that is consistent with the known conse-
quences of MT2-receptor coupling (Fig. 1). These 
observations suggest that up-regulation of the 
islet MT2 receptor in persons with the MTNR1B 
risk allele is associated with reduced insulin se-
cretion that, in vivo, may result in an impaired 
capacity to regulate blood-glucose levels properly.
The particularly exciting part of their study is 
an analysis of the effects of melatonin supple-
mentation on glucose metabolism in persons who 
are homozygous for the MTNR1B risk allele and 
in persons who are homozygous for the alterna-
tive (“nonrisk”) allele. Tuomi and colleagues found 
that a daily dose of melatonin for 3 months 
significantly reduced first-phase glucose-induced 
insulin secretion in oral glucose-tolerance tests 
in all trial participants, as compared with base-
line values before treatment with melatonin. 
There was also a suggestion of an enhanced in-
hibitory effect of melatonin in persons who were 
homozygous for the MTNR1B risk allele, as com-
pared with the effect of melatonin in persons 
who were homozygous for the alternative allele, 
although it is not clear whether the authors ap-
plied a test to determine whether this apparent 
enhancement was significant. The inhibition of 
insulin secretion is probably mediated by the 
direct activation of beta-cell MT2 receptors by 
melatonin, a mechanism that is consistent with 
the results of the in vitro experiments with rat 
beta cells.2 Further experiments with isolated 
human islets may be required in order to define 
the direct effects of melatonin on beta-cell func-
tion more fully; intriguingly, an earlier report 
suggested that melatonin stimulates the release 
of insulin from human islets in vitro.3
Melatonin is normally released from the pi-
neal gland at night to entrain circadian rhythms. 
Its pattern of secretion is disrupted by abnormal 
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Figure 1. Effect of Variant MTNR1B on Melatonin Signaling in Islet Beta Cells.
Pancreatic-islet beta cells express MT2 receptors that are encoded by the MTNR1B gene. Under normal conditions, melatonin, which is 
released from the pineal gland at night, binds to this receptor to reduce ATP conversion to cyclic AMP (cAMP) by the enzyme adenylate 
cyclase. This situation results in reduced activation of the stimulatory protein kinase A, so insulin secretion in response to glucose me-
tabolism is inhibited (Panel A). In persons who have a variant in MTNR1B that is associated with risk of type 2 diabetes, MT2 receptors 
are up-regulated on islet beta cells, which effects a more robust inhibition of cAMP generation and therefore greater inhibition of glucose-
stimulated insulin secretion than in those without the variant (Panel B). This reduction in insulin release may be exacerbated by eleva-
tions in circulating melatonin, especially in persons who have the MTNR1B risk variant, in whom greater numbers of MT2 receptors are 
expressed than in persons without the variant.
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sleep patterns, and epidemiologic studies have 
shown associations between shift work and sus-
ceptibility to type 2 diabetes.4 Melatonin supple-
ments are often used to treat insomnia or jet lag. 
Should we be alarmed, therefore, by the finding 
that melatonin supplementation impairs the 
glucose-induced secretion of insulin? We should 
not. The data described by Tuomi et al. indicate 
that a daily intake of 4 mg of melatonin over a 
period of 3 months did not substantially impair 
glucose tolerance, as compared with baseline, 
and that blood-glucose levels returned to normal 
within 2 hours after dosing. Melatonin supple-
mentation for jet lag is usually taken for only a 
few days, and for treatment of insomnia it is 
taken at doses that are less than 4 mg daily, so 
any deterioration in insulin release is unlikely 
to be as marked as that seen in the trial reported 
by Tuomi and colleagues.
Nonetheless, the study raises the question of 
whether the gain-of-function variant in MTNR1B 
could predispose persons to glucose intolerance 
or type 2 diabetes under conditions of insulin 
resistance such as obesity, in which beta cells 
are required to compensate for reduced insulin 
sensitivity by secreting more insulin and may be 
hindered in doing so by melatonin supplementa-
tion. Further studies testing the effects of mela-
tonin on glucose intolerance in obese persons 
are warranted.
The study also raises the question of whether 
MT2-receptor antagonists could be developed as 
therapies for type 2 diabetes, to maximize the 
glucose-induced insulin-secretory response by 
blocking the inhibitory cascade that is activated 
by melatonin in beta cells. This question is cer-
tainly worthy of consideration, but MT2 recep-
tors are expressed in a range of extrapineal tis-
sues, both central and peripheral, which raises 
the specter of off-target effects. The identifica-
tion of MTNR1B variation as a risk factor and the 
MT2 receptor as a potential therapeutic target is 
exciting, but it is worth bearing in mind that 
this receptor is just one of nearly 300 GPCRs 
that are expressed by human islets5 and that 
other GPCRs may also be good candidates. The 
fact that agonists of the glucagon-like peptide 1 
receptor are routinely used to treat type 2 diabetes 
supports this point.
Disclosure forms provided by the authors are available at 
NEJM.org.
From the Diabetes Research Group, Division of Diabetes and 
Nutritional Sciences, King’s College London, London.
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